186 related articles for article (PubMed ID: 24669831)
1. An inhibitor's-eye view of the ATP-binding site of CDKs in different regulatory states.
Echalier A; Hole AJ; Lolli G; Endicott JA; Noble ME
ACS Chem Biol; 2014 Jun; 9(6):1251-6. PubMed ID: 24669831
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
Jeffrey PD; Tong L; Pavletich NP
Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
[TBL] [Abstract][Full Text] [Related]
3. Cyclin-dependent kinase inhibitors.
Fischer PM; Endicott J; Meijer L
Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
[TBL] [Abstract][Full Text] [Related]
4. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.
Hashimoto Y; Kohri K; Kaneko Y; Morisaki H; Kato T; Ikeda K; Nakanishi M
J Biol Chem; 1998 Jun; 273(26):16544-50. PubMed ID: 9632724
[TBL] [Abstract][Full Text] [Related]
5. ATP-site directed inhibitors of cyclin-dependent kinases.
Gray N; Détivaud L; Doerig C; Meijer L
Curr Med Chem; 1999 Sep; 6(9):859-75. PubMed ID: 10495356
[TBL] [Abstract][Full Text] [Related]
6. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
Park H; Yeom MS; Lee S
Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors.
Pavletich NP
J Mol Biol; 1999 Apr; 287(5):821-8. PubMed ID: 10222191
[TBL] [Abstract][Full Text] [Related]
8. Selectivity and potency of cyclin-dependent kinase inhibitors.
Sridhar J; Akula N; Pattabiraman N
AAPS J; 2006 Mar; 8(1):E204-21. PubMed ID: 16584130
[TBL] [Abstract][Full Text] [Related]
9. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
[TBL] [Abstract][Full Text] [Related]
10. Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism.
Heitz F; Morris MC; Fesquet D; Cavadore JC; Dorée M; Divita G
Biochemistry; 1997 Apr; 36(16):4995-5003. PubMed ID: 9125522
[TBL] [Abstract][Full Text] [Related]
11. CDK versus GSK-3 inhibition: a purple haze no longer?
Fischer PM
Chem Biol; 2003 Dec; 10(12):1144-6. PubMed ID: 14700620
[TBL] [Abstract][Full Text] [Related]
12. Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.
Fischer PM; Lane DP
Curr Med Chem; 2000 Dec; 7(12):1213-45. PubMed ID: 11032968
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity.
Kriwacki RW; Hengst L; Tennant L; Reed SI; Wright PE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11504-9. PubMed ID: 8876165
[TBL] [Abstract][Full Text] [Related]
14. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors.
Keenan SM; Geyer JA; Welsh WJ; Prigge ST; Waters NC
Comb Chem High Throughput Screen; 2005 Feb; 8(1):27-38. PubMed ID: 15720195
[TBL] [Abstract][Full Text] [Related]
15. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Kalra S; Joshi G; Munshi A; Kumar R
Eur J Med Chem; 2017 Dec; 142():424-458. PubMed ID: 28911822
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.
Vlach J; Hennecke S; Amati B
EMBO J; 1997 Sep; 16(17):5334-44. PubMed ID: 9311993
[TBL] [Abstract][Full Text] [Related]
17. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
[TBL] [Abstract][Full Text] [Related]
18. Targeting malaria with specific CDK inhibitors.
Geyer JA; Prigge ST; Waters NC
Biochim Biophys Acta; 2005 Dec; 1754(1-2):160-70. PubMed ID: 16185941
[TBL] [Abstract][Full Text] [Related]
19. Two different bindings of p21 Cdk inhibitor to cyclin/Cdk complex.
Nakanishi M; Kagawa Y; Takahashi H; Matsushime H
Leukemia; 1997 Apr; 11 Suppl 3():356-7. PubMed ID: 9209388
[TBL] [Abstract][Full Text] [Related]
20. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.
Song Y; Kesuma D; Wang J; Deng Y; Duan J; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2004 Apr; 317(1):128-32. PubMed ID: 15047157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]